Applications of Lipid Nanocarriers for Solid Tumors Therapy: Literature Review

• Autor(a) principal: Correia de Oliveira, Lidiane
• Data de Publicação: 2012
• Outros Autores: Fleury Taveira, Eliseu José, Gomes Souza, Leonardo, Neves Marreto, Ricardo, Martins Lima, Eliana, Fleury Taveira, Stephânia
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista Brasileira de Cancerologia (Online)
• Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/581
• topic: Lipossomos; Nanopartículas; Lipídeos; Neoplasias; Antineoplásicos; Revisão; Liposomes; Nanoparticles; Lipids; Neoplasms; Antineoplastics; Review; Liposomas; Nanopartículas; Lípidos; Neoplasias; Antineoplásicos; Revisión

Introduction: Lipid nanocarriers are systems used to target drugs to its site of action and have attracted attention of the scientific community because they are biocompatible and biodegradable. These systems can target drugs to solid tumors, providing sustained drug release in the site of action, thus increasing the utility of the antineoplastic chemotherapy. Objective: To review the available literature on in vivo experiments with lipid nanocarriers containing cytotoxic drugs for solid tumors treatment. Method: A search study was carried out in Pubmed® database from 2007 to 2011, with subject descriptors: liposomes, lipid nanoparticles, cancer and in vivo, with the boolean operator “and” among them, in English. Results: 1,595 papers related to the use of liposomes and 77 related to lipid nanoparticles were found. Few studies reported in vivo experiments with lipid nanoparticles (28 papers) compared to liposomes (472 papers), since liposomes were developed two decades before lipid nanoparticles. Four liposomal medicines have already been approved and are used in the clinic while only one medicine containing lipid nanoparticles is in phase I of clinical studies. Conclusion: The number of papers related to the use of nanotechnology for cancer treatment is increasing rapidly, making important to know the different kinds of nanocarriers and, especially, those which are already used in the clinic. There are only few clinical studies on lipid nanocarriers; however, these systems present an enormous potential to improve the clinical practice in oncology.